Form 4: 10x Genomics Executive Sells Shares for Tax Obligations

President and Chief Scientific Officer Benjamin J. Hindson sold 11,595 shares of 10x Genomics to cover tax withholding requirements.

Summary

• Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc., sold 11,595 shares of Class A Common Stock.
• The transaction occurred on May 22, 2026, at an average price of $24.4415 per share.
• Following the transaction, Hindson retains beneficial ownership of 502,000 shares of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is purely administrative and related to tax obligations rather than a discretionary divestment.

Positives

• The sale was a routine transaction specifically executed to satisfy tax withholding obligations related to the vesting of restricted stock units.

Negatives

• The transaction represents a reduction in the direct equity stake held by a key executive.

Risks

• None identified; this is a standard regulatory disclosure for tax-related equity liquidation.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Management Comments

• The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that routine insider selling to cover tax liabilities upon the vesting of equity awards is a standard practice in the biotechnology sector and does not typically signal a change in executive sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation and tax compliance.
• The volume of shares sold is consistent with typical tax-withholding requirements for senior executives in mid-to-large cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned for tax compliance.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

10x Genomics, TXG, Insider Trading, Form 4, Biotechnology, Equity Vesting